Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense is Issued Patent for Inflammation Imaging Product

Pittsburgh, PA (May 15, 2015) —Celsense, Inc., announced today that it has received a Notice of Allowance for Japanese Patent Application Number 2011/507466 with claims covering its MRI inflammation imaging product, V-Sense. 

V-Sense is a perfluorocarbon tracer agent used to label leukocytes (white blood cells) in situ, making them detectable using magnetic resonance imaging (“MRI”).  Invented by Eric Ahrens and Jelena Janjic, V-Sense can be used to detect and measure site specific inflammation in a wide variety of disease models in preclinical studies.    

To date, more than 30 customers in 6 countries have used V-Sense to develop relevant immunological data in preclinical studies, and the results have been reported in over 25 peer reviewed academic papers.  V-Sense is currently available for use in preclinical research.  The company is currently seeking a development partner to fund translation of V-Sense to clinical use.

The patent, COMPOSITIONS AND METHODS FOR PRODUCING EMULSIONS FOR NUCLEAR MAGENTIC RESONANCE TECHNIQUES AND OTHER APPLICATIONS, includes claims covering methods and compositions for the use of perfluorocarbon tracer agents to detect and image cells that mediate inflammation using nuclear magnetic resonance.

“We are delighted to add this patent to our growing intellectual property portfolio and to extend our leadership position in cellular and molecular imaging tools.  We are currently seeing a lot of interest in V-Sense to study cardiac inflammation, the inflammation associated with NAFLD, and the role of tumor associated macrophage,” said Charlie O’Hanlon, President and CEO of Celsense.

About Celsense, Inc.
Celsense, Inc. develops and markets novel products that enable the non-invasive imaging of populations of cells using in vivo using MRI. Customers include leading pharmaceutical and biotechnology companies and medical research centers worldwide. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com